Iranian Firm Takes Effective Step to Launch Several Active Pharmaceutical Ingredient Production Lines
“The production of active pharmaceutical ingredients is not possible without research and development, which is why the R&D center was launched from the very beginning. This center paved the ground for us to make the products needed by the market and introduce them to the market through contract manufacturing,” said Mohammad Reza Abdollahi, the managing director of the company.
“By identifying empty capacities in the active pharmaceutical ingredient production industry, we collaborated with some pharmaceutical factories and succeeded in making our products,” he added.
“So far, the R&D unit has been developed through three quantitative and qualitative stages, and now, with a team of 20 experts, we have succeeded in developing 11 new molecules, 7 of which are knowledge-based,” Abdollahi said.
He described the production of the drug Telmisartan, a blood pressure and cardiovascular control drug, as among the achievements of this team, saying that his company’s project will save over $10 million in foreign exchange annually.
Telmisartan is used alone or in combination with other medications to treat high blood pressure.
Telmisartan is also used to decrease the chance of heart attack, stroke, or death in people 55 years of age or older who are at high risk for cardiovascular disease.
4155/v
